Fundraising Fox

Century Therapeutics, Inc.

NASDAQ: IPSCUnicorn · $1.1B

Philadelphia, US · Founded 2019 · 3 known investors

Find your way into Century Therapeutics, Inc.

25 people in our graph share verified history with the Century Therapeutics, Inc. team — schools, employers, funds. One of them is your warm intro.

Steve Holtzmanunlockedknows Chad A. Cowan · together at Cellular Intelligence (overlapped)
×3knows the team · via Cellular Intelligence
×5knows the team · via The University of Texas Southwestern Medical School
×2knows the team · via Harvard Stem Cell Institute
knows the team · via Clade Therapeutics

Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer. The company aims to make cell therapies more effective, tolerable, accessible and affordable than existing treatments.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

BPBrent Pfeiffenberger
Brent PfeiffenbergerinChief Executive OfficerBrent Pfeiffenberger is President and CEO of Century Therapeutics, which develops allogeneic iPSC-derived cell therapies for autoimmune diseases and cancer. He brings broad healthcare experience from roles across multiple geographies.
GR
Gregory RussottiChief Technology and Manufacturing Officer
CCChad Cowan
Chad CowaninChief Scientific OfficerChad Cowan is Chief Scientific Officer at Century Therapeutics, bringing experience in stem cell research, iPSC-derived cell therapy development, genetic engineering, and genome editing. He has led discovery and translational research programs in immuno-oncology and regenerative medicine.
TB
Toshikazu BanNamed on SEC filing
JJ
Joseph JimenezNamed on SEC filing
OF
Osvaldo Flores, Ph.D.Named on SEC filing
DC
Douglas CarrNamed on SEC filing
CB
Cynthia ButittaNamed on SEC filing
JE
Juergen EckhardtNamed on SEC filing

Board

CRCarlo Rizzuto
Carlo Rizzutoin𝕏Board directorManaging Director at Versant Ventures
ECEli Casdin
Eli Casdinin𝕏Board directorChief Investment Officer and Founder at Casdin Capital

Investors · 3

RA CapitalBoston
Casdin CapitalreportedNew Yorkvia Eli Casdin · board
Versant VenturesreportedSan Francisco · $250K – $5Mvia Carlo Rizzuto · board

Reported raises · per SEC filings

Form D private placements
▶$160MofferedMar 2021 · 22 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Toshikazu BanDirector
  • Carlo RizzutoDirector
  • Joseph JimenezDirector
  • Osvaldo Flores, Ph.D.Executive Officer, Director
  • Douglas CarrExecutive Officer
  • Eli CasdinDirector
  • Cynthia ButittaDirector
  • Juergen EckhardtDirector
Offering amount
$160M
First sale
Feb 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$1.1Bvaluation at IPOJun 2021 · $20.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

In the news

Century Therapeutics SVP sells $520 in stock for tax withholding By Investing.cominvesting.com · Sep 2026Point72 reports 5.96M shares (3.3%) of Century Therapeutics | IPSC SEC Filing - Form SCHEDULE 13G/Astocktitan.net · May 2026According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Century Therapeutics, Inc. has successfully sold common stock worth $18.4 million through investment bank TD Cowen. | Bitget Newsbitget.com · Mar 2026Century Therapeutics registers 176M shares for resale | IPSC SEC Filing - Form S-3stocktitan.net · Feb 2026Century Therapeutics, Inc. Business Model, Financials & Competitors (2026) | AskCyborgaskcyborg.com · Jun 2024Century Therapeutics, Inc. (IPSC): history, ownership, mission, how it works & makes moneydcf-analysis.com · Jun 2024

Frequently asked questions

What does Century Therapeutics, Inc. do?
Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer. The company aims to make cell therapies more effective, tolerable, accessible and affordable than existing treatments.
Who are Century Therapeutics, Inc.'s investors?
Century Therapeutics, Inc.'s investors include RA Capital, Casdin Capital, Versant Ventures.
Where is Century Therapeutics, Inc. headquartered?
Century Therapeutics, Inc. is headquartered in Philadelphia, US.